eik1001
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 6, 2024 (NCT06246110)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 8AGONIST
TLR8 agonist
- Toll-like receptor 7AGONIST
TLR7 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06697301 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | Eikon Therapeutics, Merck |
| NCT06246110 | Phase 2 | Feb 6, 2024 | Eikon Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eikon Therapeutics | For profit | 2 | 2 | 2 | 2024 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1